Anticancer research · 2015
High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zimling Zarah Glad, Santoni-Rugiu Eric, Bech Cecilia, Sørensen Jens Benn
Аннотация
BACKGROUND/AIM: A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. The present study aimed to further explore this finding in malignant pleural mesothelioma (MPM).
MATERIALS AND METHODS: Seventy-one patients with MPM receiving first-line chemotherapy with cisplatin-vinorelbine (CiV group, n=54) or carboplatin-pemetrexed (CaP group, n=17) were included. Formalin-fixed paraffin-embedded tumor specimens were analyzed by immunohistochemistry (IHC) for RRM1 expression using an H-score.
RESULTS: In 66 patients eligible for IHC, the H-score was ≥upper quartile in 21 (RRM1-positive) and <upper quartile (RRM1-negative) in 45 cases. The long-term (2-year) survival rate for patients with RRM1-negative MPM in the CiV-treated group was significantly superior to that for patients with RRM1-positive MPM (47% versus 13%, p=0.002). No difference occurred in the CaP-treated group.
CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC.
MATERIALS AND METHODS: Seventy-one patients with MPM receiving first-line chemotherapy with cisplatin-vinorelbine (CiV group, n=54) or carboplatin-pemetrexed (CaP group, n=17) were included. Formalin-fixed paraffin-embedded tumor specimens were analyzed by immunohistochemistry (IHC) for RRM1 expression using an H-score.
RESULTS: In 66 patients eligible for IHC, the H-score was ≥upper quartile in 21 (RRM1-positive) and <upper quartile (RRM1-negative) in 45 cases. The long-term (2-year) survival rate for patients with RRM1-negative MPM in the CiV-treated group was significantly superior to that for patients with RRM1-positive MPM (47% versus 13%, p=0.002). No difference occurred in the CaP-treated group.
CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC.
Предметные рубрики MeSH
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCisplatinCohort StudiesFemaleHumansImmunohistochemistryLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMiddle AgedPleural NeoplasmsRibonucleoside Diphosphate ReductaseTreatment OutcomeTumor Suppressor ProteinsVinblastineVinorelbine